Kalaris Therapeutics grants 9,000 stock options
Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock. The options have an exercise price of $4.7200 per share and expire on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service.
Insider Trade Summary
Grant/Award: 9,000 shares
Grant/Award
1 txn
Insider
Ferrara Napoleone
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 9,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,000 options (Direct)
Footnotes (1)
- F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Key Figures
Option grant size: 9,000 shares
Exercise price: $4.7200 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Option grant size
9,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$4.7200 per share
Exercise price for 9,000 stock options
Expiration date
June 2, 2036
Option award expiry
Vesting date
Earlier of June 3, 2027 or 2027 meeting
Full vesting, subject to continued service
Post-transaction options held
9,000 options
Total derivative securities following this grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more
5 terms
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy) for 9,000 shares"
exercise price financial
"The option has an exercise price of $4.7200 per share of common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options carry an expiration date of June 2, 2036 for the award"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"The underlying security title is listed as Common Stock for this option"
vest in full financial
"The shares underlying the option are scheduled to vest in full on the earlier date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Kalaris Therapeutics (KLRS) report for Ferrara Napoleone?
Kalaris Therapeutics reported that director Ferrara Napoleone received a grant of stock options for 9,000 shares. These options give the right to buy common stock at a fixed price and represent a compensation-related award rather than an open-market purchase or sale.
What are the key terms of Ferrara Napoleone’s stock option grant at KLRS?
Ferrara Napoleone’s grant covers 9,000 shares of Kalaris Therapeutics common stock with an exercise price of $4.7200 per share. The options expire on June 2, 2036, giving a long window to exercise once the award has vested under the stated conditions.
When do Ferrara Napoleone’s Kalaris Therapeutics options vest?
The 9,000-share option award is scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on Ferrara Napoleone’s continued service with the company through that vesting date.
Is Ferrara Napoleone’s Form 4 transaction a buy or a compensation grant at KLRS?
Ferrara Napoleone’s Form 4 reports a compensation-related grant, coded as a grant, award, or other acquisition. It reflects an option award to acquire 9,000 shares at $4.7200 per share, not an open-market purchase or sale of Kalaris Therapeutics stock.
How many Kalaris Therapeutics derivative securities does Ferrara Napoleone hold after this filing?
After this reported transaction, Ferrara Napoleone holds 9,000 stock options in Kalaris Therapeutics, corresponding to 9,000 underlying shares of common stock. This reflects the full amount of the newly granted award reported in the Form 4 for this director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
